Fusion-harboring mast cells can explain molecular positivity in flow cytometric MRD-negative core-binding factor AML

2.

Qin

W

,

Chen

X

,

Shen

HJ

, et al.

Comprehensive mutation profile in acute myeloid leukemia patients with RUNX1-RUNX1T1 or CBFB-MYH11 fusions

.

Turk J Haematol

.

2022

;

39

(

2

):

84

-

93

.

3.

Liu

P

,

Liu

JP

,

Sun

SJ

, et al.

CBFB-MYH11 fusion sequesters RUNX1 in cytoplasm to prevent DNMT3A recruitment to target genes in AML

.

Front Cell Dev Biol

.

2021

;

9

:

675424

.

4.

Beghini

A

.

Core binding factor leukemia: chromatin remodeling moves towards oncogenic transcription

.

Cancers (Basel)

.

2019

;

11

(

12

):

1973

.

5.

Downing

JR

.

The AML1-ETO chimaeric transcription factor in acute myeloid leukaemia: biology and clinical significance

.

Br J Haematol

.

1999

;

106

(

2

):

296

-

308

.

6.

Dong

ZMD

,

Ramakrishnan

A

,

Chauncey

TR

, et al.

No adverse effect of residual neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia with T(8;21)(Q22;Q22); Runx1-Runx1t1 after bone marrow transplantation

.

Ann Clin Pathol

.

2014

;

2

(

1

):

1009

.

7.

Hilmi

FAI

,

Al-Sabbagh

A

,

Soliman

DS

, et al.

Acute myeloid leukemia with Inv(16)(p13q22) associated with hidden systemic mastocytosis: case report and review of literature

.

Clin Med Insights Blood Disord

.

2017

;

10

:

1179545x17700858

.

8.

Pullarkat

ST

,

Pullarkat

V

,

Lagoo

A

, et al.

Characterization of bone marrow mast cells in acute myeloid leukemia with t(8;21) (q22;q22); RUNX1-RUNX1T1

.

Leuk Res

.

2013

;

37

(

11

):

1572

-

1575

.

9.

Pullarkat

V

,

Bedell

V

,

Kim

Y

, et al.

Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone

.

Leuk Res

.

2007

;

31

(

2

):

261

-

265

.

10.

Wang

YY

,

Zhou

GB

,

Yin

T

, et al.

AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec

.

Proc Natl Acad Sci U S A

.

2005

;

102

(

4

):

1104

-

1109

.

11.

Xie

W

,

Wang

SA

,

Yin

CC

, et al.

Acute myeloid leukemia with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and KIT Exon 8 mutation is associated with characteristic mastocytosis and dismal outcomes

.

Exp Mol Pathol

.

2019

;

108

:

131

-

136

.

12.

Heuser

M

,

Freeman

SD

,

Ossenkoppele

GJ

, et al.

2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party

.

Blood

.

2021

;

138

(

26

):

2753

-

2767

.

13.

Escribano

L

,

Orfao

A

,

Díaz-Agustin

B

, et al.

Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications

.

Blood

.

1998

;

91

(

8

):

2731

-

2736

.

14.

Metcalfe

DD

.

Mast cells and mastocytosis

.

Blood

.

2008

;

112

(

4

):

946

-

956

.

15.

Swerdlow

SH

,

Campo

E

,

Harris

NL

, et al. Myeloproliferative neoplasms. In:

Swerdlow

SH

,

Campo

E

,

Harris

NL

, eds.

WHO classification of tumours of haematopoietic and lymphoid tissue

. 4th ed..

Lyon; International Agency for Research on Cancer

;

2008

.

16.

Carter

MC

,

Metcalfe

DD

,

Komarow

HD

.

Mastocytosis

.

Immunol Allergy Clin North Am

.

2014

;

34

(

1

):

181

-

196

.

17.

Cherian

S

,

McCullouch

V

,

Miller

V

,

Dougherty

K

,

Fromm

JR

,

Wood

BL

.

Expression of CD2 and CD25 on mast cell populations can be seen outside the setting of systemic mastocytosis

.

Cytometry B Clin Cytom

.

2016

;

90

(

4

):

387

-

392

.